M Azoulay
Mar 1, 2011
Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland
Brändle M, Azoulay M, Greiner R. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther 2011; 49:217-230.
Mar 1, 2011Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland
Mar 1, 2011Int J Clin Pharmacol Ther 2011; 49:217-230
Brändle Michael, Azoulay M, Greiner R -A
more
Apr 1, 2007
Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
Brändle M, Azoulay M, Greiner R. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. International journal of clinical pharmacology and therapeutics 2007; 45:203-20.
Apr 1, 2007Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
Apr 1, 2007International journal of clinical pharmacology and therapeutics 2007; 45:203-20
Brändle Michael, Azoulay M, Greiner R A
more